Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Clinical trial NCT05294731 · RECRUITING

Trial details

NCT number: NCT05294731
Sponsor: BeiGene
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

B-cell Malignancy Non-Hodgkin Lymphoma Mantle Cell Lymphoma Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Waldenström Macroglobulinemia Marginal Zone Lymphoma Follicular Lymphoma DLBCL Unclassifiable Richter's Transformation

Start date: 2022-05-06
Primary completion: 2029-01-31
Enrollment: 146

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.